Rhône-Poulenc Rorer Inc. regulatory update

RPR submitted an NDA to the FDA for Rilutek (riluzole) to treat amyotrophic lateral sclerosis (ALS). The Collegeville, Penn., company said it will begin this week to file applications on a worldwide ...